Biocon Sdn. Bhd. Enters Malaysia Book of Records as the First & the Largest Integrated Insulin Manufacturing Facility

  • Posted by: Biocon Biologics

Biocon Q1FY23 Revenue at Rs 2,217 Cr, Up 23%; Net Profit at Rs 144 Cr, Up 71%; Core EBITDA at Rs 660 Cr Up 25%

  • Posted by: Biocon Biologics

Biocon Biologics Receives EU GMP Certification for Its New Biologics Manufacturing Facility in Bengaluru

  • Posted by: Biocon Biologics

Biocon Biologics issues a statement in response to the media reports related to bribery allegations

  • Posted by: Biocon Biologics

Biocon Biologics Denies Bribery Allegations

  • Posted by: Biocon Biologics

University of Glasgow officially Opens Mazumdar-Shaw Advance Research Centre

  • Posted by: Biocon Biologics

Biocon Biologics and Viatris Launch Abevmy® (bBevacizumab), Their Third Oncology Biosimilar, in Canada

  • Posted by: Biocon Biologics

Biocon Q4FY22 Revenue at Rs 2,476 Cr, Up 21%; Core EBITDA at Rs 815 Cr, Up 37% ; PBT(before Exceptional Items) at Rs 384 Cr, Up 9%

  • Posted by: Biocon Biologics

Biocon Biologics’ Insugen® Awarded a Three-Year Contract by Ministry of Health, Malaysia

  • Posted by: Biocon Biologics

Biocon Biologics’ Partner Receives Positive EU CHMP Opinion for Biosimilar Human Insulin for IV Infusion

  • Posted by: Biocon Biologics
Share